Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Beginning with phenylketonuria, dietary therapy for inborn errors has focused primarily on the restriction of the precursor to an affected catabolic pathway in an attempt to limit the production of potential toxins. Anaplerotic therapy is based on the concept that there may exist an energy deficit in these diseases that might be improved by providing alternative substrate for both the citric acid cycle (CAC) and the electron transport chain for enhanced ATP production. This article focuses on this basic problem, as it may relate to most catabolic disorders, and provides our current experience involving inherited diseases of mitochondrial fat oxidation, glycogen storage, and pyruvate metabolism using the anaplerotic compound triheptanoin. The observations have led to a realization that ‘inter‐organ’ signalling and ‘nutrient sensors’ such as adenylate monophosphate mediated‐protein kinase (AMPK) and mTOR (mammalian target of rapamycin) appear to play a significant role in the intermediary metabolism of these diseases. Activated AMPK turns on catabolic pathways to augment ATP production while turning off synthetic pathways that consume ATP. Information is provided regarding the inter‐organ requirements for more normal metabolic function during crisis and how anaplerotic therapy using triheptanoin, as a direct source of substrate to the CAC for energy production, appears to be a more successful approach to an improved quality of life for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status
Hardie, D. G. (2003) · Endocrinology · doi:10.1210/en.2003-0982 · Cited by 994 · cited 1×
“It is a protein kinase that places PO4 on serine residues in many proteins, including enzymes (Hardie 2003).”
Background
Cited by
Brain Glucose Metabolism: Integration of Energetics with Function
Dienel, G. A. (2019) · Physiological Reviews · doi:10.1152/physrev.00062.2017 · Cited by 865
Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle
Knottnerus, S. J. G., Bleeker, J. C., Wüst, R. C. I., Ferdinandusse, S., IJlst, L., Wijburg, F. A., Wanders, R. J. A., Visser, G., & Houtkooper, R. H. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9448-1 · Cited by 331
Glycogen Storage Disease Type III diagnosis and management guidelines
Kishnani, P. S., Austin, S. L., Arn, P., Bali, D. S., Boney, A., Case, L. E., Chung, W. K., Desai, D. M., El-Gharbawy, A., Haller, R., et al. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181e655b6 · Cited by 311
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
Park, M. J., Aja, S., Li, Q., Degano, A. L., Penati, J., Zhuo, J., Roe, C. R., & Ronnett, G. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109527 · Cited by 62
“flux and replenish oxaloacetate (OAA) so that acetyl groups can enter the TCA cycle at citrate synthase[23,24,26].”
BackgroundSelf-citation
Metadata
- Authors
- Roe, C. R., & Mochel, F.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2005-11-30
- Volume
- 29
- Issue
- 2-3
- Pages
- 332-340
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2036693767
- Cited by
- 128
- References
- 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. https://app.cochat.ai/papers/10.1007/s10545-006-0290-3
- The paper
- Roe, C. R., & Mochel, F. (2006). Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-006-0290-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.